The United States Food and Drug Administration approved (Insulin glargine injection), a long-acting human insulin analog to achieve optimal glycemic control in type-1 and type-2 diabetics including adults and children.
Basaglar dose should be personalized and administered subcutaneously once daily, preferably at the same time of every day. Basaglar is contraindicated in diabetics with hypoglycemia episodes.
Some of the severe adverse events include hypotension, allergic reactions, anaphylaxis, angioedema, shock and generalized skin reactions. Other common adverse reactions include rashes, edema, weight gain, itching and rashes.